Genetic profiling and cardiovascular phenotypic spectrum in a Chinese cohort of Loeys-Dietz syndrome patients

Hang Yang\textsuperscript{1†}, Yanyun Ma\textsuperscript{1†}, Mingyao Luo\textsuperscript{2†}, Guoyan Zhu\textsuperscript{1}, Yinhui Zhang\textsuperscript{1}, Binbin Li\textsuperscript{1}, Chang Shu\textsuperscript{2*} and Zhou Zhou\textsuperscript{1*}

Abstract

Background: Loeys-Dietz syndrome (LDS) is a rare connective tissue disorder for which 6 genes in the TGF-\(\beta\) pathway have been identified as causative. With the widespread use of genetic testing, the range of known clinical and genetic profiles has broadened, but these features have not been fully elucidated thus far.

Methods and results: Using gene panel sequencing or whole exome sequencing, we identified 54 unique rare variants in LDS genes in 57 patients with thoracic aneurysms/dissections, including 27 pathogenic mutations (P + LP) and 27 variants of unknown significance (VUS LP + VUS). Genotype-phenotype correlation analysis revealed that carriers with P/LP/VUS LP variants in \(TGFBR1/TGFBR2/SMAD3\) genes had significantly more severe cardiovascular features (cardiovascular death/dissection) than carriers with VUSs in these 3 genes at an early age and had less favorable event-free survival. Additionally, carriers with VUS in combination with other risk factors, such as hypertension, might be prone to developing an aortic dissection, as indicated by the fact that 5/8 (62.5\%) patients with VUSs in our cohort developed aortic dissections in the presence of hypertension, compared with 25.0\% (3/12) in the absence of hypertension (\(p = 0.047\)).

Conclusions: To date, this was the largest cohort of LDS patients ever reported in China, and the present study expanded the known mutation and phenotypic spectra of LDS, which might help refine our knowledge of LDS.

Keywords: Loeys-Dietz syndrome, Genetic testing, Phenotypic spectrum

Background

Loeys-Dietz syndrome (LDS) is an autosomal dominant connective tissue disorder characterized by cardiovascular deformity (aortic aneurysms and/or dissections, multiple arterial aneurysms and arterial tortuosity) and skeletal problems (arachnodactyly, pectoral deformities, scoliosis and joint laxity) as well as other craniofacial and cutaneous abnormalities, sharing some features with Marfan syndrome (MFS) and differing in other respects [1]. Initially, LDS was generally thought to be more aggressive than MFS, with dissections at younger ages and at smaller arterial diameters, which led to a lower threshold (4.2 cm) for prophylactic surgical intervention by the 2010 American Heart Association (AHA) guideline [2].

Mutations in \(TGFBR1\) and \(TGFBR2\) were discovered in 2005 as the first known causative mutations for LDS [1]. Subsequently, other genes in the TGF-\(\beta\) signaling pathway, including \(SMAD3\) [3], \(TGFBR2\) [4, 5], \(SMAD2\) [6] and \(TGFBR3\) [7], were also found to be associated with LDS. Subsequently, the definition of LDS expands to all patients who carry a heterozygous pathogenic variant in any of these six genes in combination with the presence...
of an artery aneurysm/dissection or corresponding systemic manifestations.

The full spectrum of phenotypes and mutations associated with TGFBR1- and TGFBR2-related LDS has been extensively described and well recognized. However, for the more recently identified LDS genes (TGFBR2, TGFBR3 and SMAD2, SMAD3), the phenotypic and genotypic spectra have not yet been fully elucidated and need further expansion. Current studies reveal that patients with TGFBR2-, TGFBR3- and SMAD2-related LDS tend to have mild cardiovascular features and that their mutations have lower penetrance than those that cause TGFBR1- and TGFBR2-related LDS [4, 7, 8]. Therefore, further clinical and genetic data on LDS from around the world should be collected and analyzed to define gene-specific vascular treatment guidelines for LDS, rather than treating them all with the same approach. In this study, we identified 54 unique rare variants in LDS genes in aortic aneurysm/dissection patients and summarized the clinical data of these patients, especially their vascular phenotypic data, which could help further refine our knowledge of LDS.

Materials and methods

Patients

More than 900 patients with aortic disease and/or diagnosed or suspected MFS had been referred from the Aortic Surgery Department to the Center for Molecular Diagnosis at Fuwai Hospital and had undergone panel testing involving 15 genes (ACTA2, COL3A1, FBN1, FBN2, MYH11, MYLK, NOTCH1, PRKG1, SKI, SLC2A10, SMAD3, SMAD4, TGFB2, TGFB1, TGFB2) since Feb 2014 [9]. Furthermore, more than 200 aortopathy patients were performed whole exome sequencing. From these patients, we included a total of 57 patients in this study, in whom a rare variant in any of the six genes TGFBR1, TGFBR2, SMAD3, SMAD2 and TGFBR3 was detected with no other suspected causative mutations.

Variant classification

Variants were analyzed for pathogenicity in line with recommendations from the American College of Medical Genetics (ACMG) and classified into one of 5 categories: benign, likely benign, unknown significance, likely pathogenic or pathogenic [10], with the detailed evidences listed behind. Besides, we additionally defined a subclassification, VUSLP, for internal use (See “Results” section for details).

Statistical analysis

Statistical analyses were performed using SPSS software. Survival curves were estimated using the Kaplan–Meier method and tested by Log Rank tests. Comparisons between continuous variables were made by Student’s t-test. A one-tailed Chi-Square test was used to test if the presence of hypertension facilitated aortic dissections in patients with VUSs in LDS genes. P value below 0.05 was considered as statistically significant.

Results

Among all of the aortopathy patients, a total of 54 unique rare variants in LDS genes were identified in 57 separate patients. Of these variants, 27 were pathogenic or likely pathogenic (summarized in Table 1), mostly in TGFBR1 and TGFB2 genes (10 in TGFBR1, 10 in TGFB2), and 24 variants remained unknown significance (summarized in Table 2). Specifically, there were 3 variants which should be classified as VUS on account of lack of evidence according to ACMG criteria. However, they were highly suspected as causative in the light of clinical information and family history. Therefore, we additionally defined a subclassification for these variants, VUSLP, for internal use (Table 1). The variants which could meet the tier “Likely Pathogenic” in ACMG criterion with one more supporting evidence, or those which could be assumed to be de novo according to the family history, were classified as VUSLP. For instance, patient AD1181’s mother suffered a sudden cardiac death at 30, therefore we could not collect her sample to perform the gene testing. However, there was a high probability that she carried the same mutation with her daughter AD1181, which was a de novo mutation because her parents and two sisters were all healthy and did not carry the mutation (Fig. 1).

The pathogenicity of the variant TGFBR2 c.1067G > C (p. Arg356Pro) initially confused us. This variant was identified in patient AD257 with characteristic signs of LDS, such as descending pseudoaneurysm, bilateral carotid tortuosity, bifid uvula and hypertelorism. This variant had been reported in five individuals with clinical features of Loes-Dietz syndrome and was found to occur de novo in three of these individuals [12–15]. Furthermore, it was absent from large population studies, and computational prediction tools and conservation analysis suggested that it might impact the protein. All evidence supported that it was a pathogenic mutation. However, we unexpectedly found that the patient’s healthy father also carried the same mutation. Upon a detailed examination of the father’s cardiac structure and arterial tree, there were no apparent abnormalities except for a slight decrease in left ventricular diastolic function. Considering that LDS was a dominant disorder with full penetrance expected at an early age and that the variant was also observed in the patient’s healthy father, this variant was finally downgraded into VUS [11] with conflicting evidence (BS2). When we reanalyzed this case after half a year, we noted that the unequal peak heights suggested probable mosaicism. To test this,
| Patient ID | Gene Transcript | Nucleotide change | Amino acid change | MAF in ExAC | MAF in gnomAD | Domain | Source | Pathogenicity | Evidence | Note |
|------------|-----------------|-------------------|------------------|-------------|--------------|--------|--------|--------------|----------|------|
| AD1413     | TGFBR1 NM_004612| c.614 T > C       | p.Ile205Thr     | .           | .            | Pkinase_Tyr | Maternal | LP           | PM2, PP3, PS2  |
| AD623-1    | TGFBR1 NM_004612| c.644G > C        | p.Arg215Pro     | .           | .            | De novo | LP      | PS2, PM2, PP3 |
| AD808      | TGFBR1 NM_004612| c.664G > A        | p.Gly222Arg     | 0.0000289   | NA           | Pkinase_Tyr | LP      | PM2, PP1_Strong, PP3 |
| AD264      | TGFBR1 NM_004612| c.683_685del      | p.228del        | .           | .            | De novo | LP      | PS2, PM2, PM4 |
| AD692-1    | TGFBR1 NM_004612| c.702_704del      | p.235del        | .           | .            | De novo | LP      | PS2, PM2, PM4 |
| AD453      | TGFBR1 NM_004612| c.722C > T        | p.Ser241Leu     | .           | .            | NA      | LP      | PM2, PS4_Supporting, PS2 |
| AD371      | TGFBR1 NM_004612| c.934G > A        | p.Gly312Ser     | 0.00000942  | 0.00000398  | NA      | LP      | PP3, PM2, PS4_Supporting, PP1_Strong |
| AD641-1    | TGFBR1 NM_004612| c.997G > A        | p.Asp333Asn     | .           | .            | De novo | LP      | PS2, PM2, PP3 |
| AD78       | TGFBR1 NM_004612| c.1459C > T       | p.Arg487Trp     | .           | .            | NA      | P       | PS4, PM2, PM5, PP1_Strong, PP3 |
| AD703-1    | TGFBR1 NM_004612| c.1459C > T       | p.Arg487Trp     | .           | .            | Maternal | P       | PS4, PM2, PM5, PP1_Strong, PP3 |
| AD1346     | TGFBR1 NM_004612| c.1459C > T       | p.Arg487Trp     | .           | .            | NA      | P       | PS4, PM2, PM5, PP1_Strong, PP3 |
| AD1362     | TGFBR1 NM_004612| c.1460G > A       | p.Arg487Gln     | .           | .            | Paternal | P       | PS2, PS3_Supporting, PS4_Moderate, PM2, PP3 |
| AD1804     | TGFBR2 NM_003242| c.95-2A > G       | .               | 0.0000293   | 0.0006      | Paternal | LP      | PVS1, PM2 |
| AD257      | TGFBR2 NM_003242| c.1067G > C       | p.Arg356Pro     | .           | .            | Pkinase_Tyr (Mosaic) | P       | PS2_Very Strong, PS4_Moderate, PM2, PP3 |
| AD22       | TGFBR2 NM_003242| c.1139T > G       | p.Leu380Arg     | .           | .            | De novo | LP      | PS2, PM2, PP3 |
| AD888      | TGFBR2 NM_003242| c.1275G > C       | p.Met425Ile     | .           | .            | Pkinase_Tyr | De novo | LP      | PS2, PM2, PP3 |
| AD1181     | TGFBR2 NM_003242| c.1363T > C       | p.Trp455Arg     | .           | .            | Pkinase_Tyr | VUS | PM2, PP3 |
| AD536      | TGFBR2 NM_003242| c.1449dupT        | p.Cys483fs      | .           | .            | Pkinase_Tyr | NA      | LP      | PVS1, PM2 |
| AD617-1    | TGFBR2 NM_003242| 1517delA          | p.Asn506fs      | .           | .            | Pkinase_Tyr | NA      | P      | PVS1, PM2, PP1 |
| AD1784     | TGFBR2 NM_003242| c.1525-1G > C     | .               | .           | .            | NA      | LP      | PVS1, PM2 |

Yang et al. Orphanet Journal of Rare Diseases (2020) 15:6 Page 3 of 9
| Patient ID | Gene | Transcript | Nucleotide change | Amino acid change | MAF in ExAC | MAF in gnomAD | Domain | Source | Pathogenicity | Evidence | Note |
|------------|------|------------|-------------------|-------------------|-------------|---------------|--------|--------|---------------|----------|------|
| AD153      | TGFBR2 | NM_003242  | c.1538 T > C      | p.Val513Ala       | .           | .             | Pkinase_ | De novo | LP            | PS2, PM2 | a    |
| AD682−1    | TGFBR2 | NM_003242  | c.1582C > T       | p.Arg528Cys       | .           | .             | De novo | P      | PS2, PP3, PM2, PS4_Moderate, PS3_ Supporting, PM5 |
| AD497      | TGFBR2 | NM_003242  | c.1609C > T       | p.Arg537Cys       | .           | .             | NA     | P      | PS2, PS3_Moderate, PS4_Moderate, PM2,PP3, PP1_Strong | a    |
| AD1550     | SMAD3  | NM_005902  | c.233_234insGG    | p.Ser78fs         | .           | .             | NA     | LP     | PVS1, PM2    |          |      |
| AD1736     | SMAD3  | NM_005902  | c.365_366insGAATCCCTACCA | p.Val122fs   | .           | .             | Paternal | LP     | PVS1, PM2    |          |      |
| AD1061     | SMAD3  | NM_005902  | c.1041delG        | p.Glu347fs        | .           | .             | NA     | LP     | PVS1, PM2    |          |      |
| AD792      | SMAD3  | NM_005902  | c.1118G > A       | p.Arg373His       | .           | .             | VUS    |        | PM2, PP3, PS3_Supporting, PS4_Supporting |
| AD1297     | SMAD3  | NM_005902  | c.1247C > T       | p.Ser416Phe       | .           | .             | De novo | LP     | PS2, PM2, PP3 |          |      |
| AD535      | SMAD3  | NM_005901  | c.593dupA         | p.His198fs        | .           | .             | De novo | LP     | PS2, PM2    |          |      |
| AD802      | TGFBR2 | NM_003238  | c.905G > A        | p.Arg302His       | .           | .             | TGF_  | Paternal | VUS$       | PM2, PM5, PP3 |      |
| AD1065     | TGFBR2 | NM_003239  | c.605_623del      | p.Phe202fs        | .           | .             | Maternal | LP     | PVS1, PM2    |          |      |
| AD631−1    | TGFBR2 | NM_003239  | c.646 + 2 T > G   | .                  | .           | .             | Paternal | LP     | PVS1, PM2    |          |      |

Note: NA not available; MAF in ExAC was the maximal allele frequency from the public version (20160423), and MAF in gnomAD was the maximal allele frequency from gnomAD v2.1.1; P, pathogenic; LP, likely pathogenic; VUS, variant of uncertain significance; a, reported in our previous article [11]; $This variant was previously classified as VUS, and then upgraded into pathogenic after the father was confirmed to carry a mosaic mutation in the same site; S This variant was confirmed to be de novo in patient AD1413's mother.
we performed deep sequencing (5000×) at this location, and the results showed that the father indeed had a mosaic mutation (Fig. 2), which convincingly explained his lack of LDS symptoms.

Patient AD535 had positive wrist sign, pectus excavatum, and moderate myopia. He was found to have an aortic root dilation with a diameter of 45 mm and a bicuspid aortic valve (BAV) upon physical examination. A SMAD2 frameshift mutation in the linker region was identified and shown to be de novo; therefore, it was classified as a likely pathogenic mutation. According to the genetic results, the patient was diagnosed with Loeys-Dietz syndrome, and an examination of his whole arterial tree was recommended to check for other arterial aneurysms. To our knowledge, this was the second report of a truncating mutation in the SMAD2 gene and further confirmed haploinsufficiency as its pathogenic mechanism.

Patient AD1162 had an aortic dissection, and also dissections in carotid artery and abdominal aorta. After a detailed investigation, we learnt that the patient had a family history of sudden deaths and retinal detachments (Fig. 3). She had lens subluxation herself. Except that her youngest brother had pectus carinatum and scoliosis, other family members had no obvious skeletal deformities.

### Table 2 Variants of unknown significance in LDS genes detected in our cohort

| Patient ID | Gene     | Transcript | Nucleotide change | Amino acid change | MAF in ExAC | MAF in gnomAD | Domain     | Source     | Pathogenicity | Evidence | Note  |
|------------|----------|------------|-------------------|-------------------|-------------|---------------|------------|------------|---------------|-----------|-------|
| AD1039     | TGFBR1   | NM_004612  | c.341C > G        | p.Thr114Ser       |             |               | VUS        | PM2, BP4   |               |           |       |
| AD1248     | TGFBR1   | NM_004612  | c.439A > G        | p.Ile147Val       | 0.0000221    | 0.000098     | VUS        | BP4        |               |           |       |
| AD589      | TGFBR1   | NM_004612  | c.605C > T        | p.Ala202Val       |             |               | VUS        | PM2, PP3   |               |           |       |
| AD823      | TGFBR1   | NM_004612  | c.767A > G        | p.His256Arg       |             |               | VUS        | PM2, PP3   |               |           |       |
| AD1802     | TGFBR1   | NM_004612  | c.782G > C        | p.Gly261Ala       |             |               | VUS        | PM2, PP3   |               |           |       |
| AD183      | TGFBR1   | NM_004612  | c.929C > T        | p.Ala310Val       | 0.0000221    | 0.00006      | VUS        | PP3        |               |           |       |
| AD436      | TGFBR1   | NM_004612  | c.935G > T        | p.Gly312Val       |             |               | VUS        | PM2, PP3   |               |           |       |
| AD1158     | TGFBR1   | NM_004612  | c.1054T > G       | p.Leu352Val       |             |               | VUS        | PM2, PP3   |               |           |       |
| AD1753     | TGFBR2   | NM_003242  | c.81C > A         | p.His27Gln        |             |               | NA         | VUS        | PM2, PP3     |           |       |
| AD1432     | TGFBR2   | NM_003242  | c.467G > T        | p.Ser150Ile       |             |               | VUS        | PM2, BP4   |               |           |       |
| AD1348     | TGFBR2   | NM_003242  | c.578G > A        | p.Arg193Gln       | 0.0000011    | 0.0000544    | TGF_beta   | Paternal   | VUS          |           |       |
| AD1156     | TGFBR2   | NM_003242  | c.617C > T        | p.Thr206Met       | 0.000377     | 0.0006       | VUS        | BP4        |               |           |       |
| AD259      | TGFBR2   | NM_003242  | c.830A > G        | p.Lys277Arg       |             |               | Pkinase_Tyr| VUS        | PM2, PP3     |           |       |
| AD667      | TGFBR2   | NM_003242  | c.1188T > G       | p.Cys396Trp       |             |               | Pkinase_Tyr| VUS        | PM2, PP3     |           |       |
| AD1162     | TGFBR2   | NM_003242  | c.1254G > T       | p.Gln418His       |             |               | Pkinase_Tyr| Maternal   | VUS          |           |       |
| AD324      | SMAD3    | NM_005902  | c.5C > T          | p.Ser2Leu         |             |               | Paternal   | VUS        | PM2          |           | ab    |
| AD1250     | SMAD3    | NM_001145103| c.53G > A         | p.Arg18Gln        |             |               | VUS        | NA         |               |           |       |
| AD76       | SMAD3    | NM_005902  | c.140_148del      | p.47_50del        |             |               | VUS        | PM2, PM4, BS2|               |           | a     |
| AD997      | SMAD3    | NM_005902  | c.364G > A        | p.Val122Met       |             |               | VUS        | PM2, PP3   |               |           |       |
| AD850      | SMAD3    | NM_005902  | c.773A > T        | p.Asp258Val       |             |               | VUS        | PM2, PP3   |               |           |       |
| AD1288     | SMAD3    | NM_005902  | c.1027T > C       | p.Phe343Leu       |             |               | VUS        | PM2, PP3   |               |           |       |
| AD148      | SMAD3    | NM_005902  | c.1027T > C       | p.Phe343Leu       |             |               | VUS        | PM2, PP3   |               |           |       |
| AD1759     | TGFBR2   | NM_003238  | c.893G > A        | p.Arg298Gln       | 0.0000221    | 0.0002       | NA         | VUS        | NA           |           |       |
| AD1599     | TGFBR2   | NM_003238  | c.1239C > G       | p.Cys413Trp       |             |               | VUS        | PM2, PP3   |               |           |       |
| AD985      | TGFBR3   | NM_003239  | c.352 + 5G > A    |                |             |               | VUS        | PM2, PP3   |               |           |       |

Note: NA not available; MAF in ExAC was the maximal allele frequency from the public version (20160423), and MAF in gnomAD was the maximal allele frequency from gnomAD v2.1.1; P, pathogenic; LP, likely pathogenic; VUS, variant of uncertain significance; a, reported in our previous article [11]; bThis variant was previously misclassified as likely pathogenic [11], and now corrected into VUS.
carried a TGFBR2 mutation (c.1254G > T, p.Gln418His), which was inherited from her mother, who suffered an aortic dissection at age 42. Therefore, she was highly suspected to be LDS. Strangely, it was commonly thought that one of the most distinguishing characteristics between LDS and MFS was that the former rarely included ocular abnormalities such as ectopia lentis or retinal detachments [16]. To exclude a FBN1 large deletion/duplication, multiplex ligation-dependent probe amplification (MLPA) assay was also performed, which was negative (Additional file 1: Figure S1). It suggested that there might be a wider spectrum of LDS than we previously realized.

To analyze the genotype-phenotype correlation, we divided the patients into two groups according to the variant pathogenicity. Considering TGFBR1/TGFBR2/SMAD3-related LDS often led to a penetrant and severe form of the disease and accounted for the vast majority in our cohort, only patients with these 3 genes were included to perform the analysis. The key cardiovascular information was listed in Table 3. When patients with P/LP/VUS\(^{LP}\) variants were set into one group and the others with VUS were set into another, event-free survival was compared and the results showed that patients with a P/LP/VUS\(^{LP}\) variant had a significant lower event-free survival rate than those with VUS \((p = 0.021\) when events defined as aortic dissections or related death; \(p = 0.025\) when events defined as dissections and aortic surgeries and related death) (Fig. 4), indicating that the presence of a pathogenic variant has possible predictive value for...
disease severity. In addition, the presence of (suspected) pathogenic variants was associated with earlier aortic dissection or surgery than the presence of VUS (29.9 y vs 38.0 y, \( p = 0.035 \)). Besides, in 20 individuals with VUSs, 8 patients had hypertension while 12 patients were with normal blood pressure, with a dissection rate of 62.5% (5/8) and 25.0% (3/12), separately (\( p = 0.047 \)) (Additional file 1: Table S1).

### Table 3 Main cardiovascular phenotypic information in two subgroups of LDS

|                      | TGFB1/TGFB2/SMAD3 | TGFB2/TGFB3/SMAD2 |
|----------------------|-------------------|-------------------|
|                      | LP/P | VUS\[^{LP}\] | VUS | LP/P | VUS\[^{LP}\] | VUS |
| Numbers              | 26   | 2      | 20  | 3    | 1      | 3   |
| Age, years           | 29.5 ± 13.3      | 34.0 ± 4.2        | 38.0 ± 11.5     | 20.3 ± 10.4  | 20   | 43.0 ± 8.5  |
| Normal or mild dilation | 3    | 0      | 4   | 3    | 0      | 0   |
| Surgery due to an aortic aneurysm/valve disease | 8    | 0      | 8   | 0    | 1      | 0   |
| Aortic dissection and related death              | 15   | 2      | 8   | 0    | 0      | 3   |

\[^{LP}\]LP indicates live patients.
Cardiovascular phenotypic spectrum
Significant clinical heterogeneity was observed in LDS patients. When first reported as a distinct disease, LDS was described as having more aggressive aortic events than MFS, with a mean age of 26 years at death [1]. A reduced threshold of 42 mm had been proposed for earlier interventions in LDS patients [2]; however, it remained controversial [20, 21]. Current studies revealed that some patients with \textit{TGFBR1}, \textit{TGFBR2} or \textit{SMAD3} mutations tended to have an early dissection at a young age or at a relatively small diameter, whereas \textit{TGFB2}, \textit{TGFB3} and \textit{SMAD2} carriers often suffered a less severe aortic event [4, 7, 8, 22]. Our data were consistent with previous studies in that all seven individuals with mutations in \textit{TGFB2}, \textit{TGFB3} or \textit{SMAD2} had relatively mild aortic events, except that patient AD985, who had the risk factors of extreme hypertension and an intronic mutation predicted to affect normal splicing, suffered an aortic dissection at 32 years of age.

Considering these two clinical forms in LDS, one more severe and penetrant than another, we only involved the severe form when analyzing the genotype-phenotype correlation, so as to avoid the interpretation bias. The results revealed that carriers with P/LP/VUS\textsuperscript{LP} variants have significantly more severe cardiovascular features (aortic dissection and related death) than carriers with VUS, at an early age and less favorable event-free survival. Notably, according to current evidence, many variants (27, 50\%) remain VUS and VUS\textsuperscript{LP}. On the one hand, some of these variants may be upgraded to likely pathogenic mutations as further supporting evidence accumulates; on the other hand, these variants may predispose patients to disease in a low-risk or low-penetrance manner and lead to aortic dissection when combined with other risk factors, such as hypertension. This possibility is well supported by our data showing that, when hypertension was present, 5/8 (62.5\%) patients with VUS in LDS genes developed aortic dissections, far more than 25.0\% (3/12) when hypertension was absent. Based on our current results, carriers with VUSs in LDS genes should receive active control of blood pressure.

Conclusions
In summary, this was the largest cohort of LDS patients ever reported in China, and we expanded the known mutation and phenotypic spectra of LDS. Genetic results not only facilitate an early and accurate diagnosis but also have possible predictive value, which needs to be further investigated because it may influence clinical care.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s13023-019-1282-3.

Additional file 1. Method S1. Multiplex ligation-dependent probe amplification (MLPA). Figure S1. MLPA assay indicated that there was no \textit{FBN1} deletion/duplication in AD1162. Table S1. Main cardiovascular phenotypic information in patients with VUSs in \textit{TGFBR1}/\textit{TGFBR2}/\textit{SMAD3} genes.

Abbreviations
ACMG: American College of Medical Genetics; AHA: American Heart Association; DN: Dominant negative; ESP: Exome Sequencing Project; HGMD: Human gene mutation database; LAP: Latency-associated peptide; LDS: Loeys-Dietz syndrome; MFS: Marfan syndrome; MLPA: Multiplex ligation-dependent probe amplification; MSSE: Multiple self-healing squamous epithelioma; STK: Serine-threonine kinase; WES: Whole exome sequencing

Acknowledgements
We thank all subjects who participated in this study.
Authors’ contributions
HY coordinated the project, carried out data analysis and wrote the manuscript. ML recruited patients and collected clinical information. YM and GZ contributed to accumulation and interpretation of clinical data. YZ performed NGS sequencing experiments and Sanger validation. BL communicated with patients and contributed to follow-up visit. CS was in charge of the clinical evaluation and sample management. ZZ was in charge of the project design and revised the manuscript. All authors read and approved the final manuscript.

Funding
This work was supported by the grant of CAMS Initiative for Innovative Medicine, China (NC2016-12M-1-016) and the National Natural Science Foundation of China (81700419).

Availability of data and materials
The data sets used and analysed during the current study are available from the corresponding author on reasonable request.

The data sets used and analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The authors give their consent for publication of this manuscript.

Consent for publication
The authors give their consent for publication of this manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 9 October 2019 Accepted: 18 December 2019

Published online: 08 January 2020

References
1. Loeyts BL, Chen J, Neptune ER, Judge DP, Podowski M, Holm T, et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet. 2005; 37(3):275–81.
2. Hiratka LF, Bakris GL, Beckman JA, Berzin RM, Carr VF, Casey DE Jr, et al. 2010 ACCF/AHA/ASCtion Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. J Am Coll Cardiol. 2010;55(S1):e27–e129.
3. van de Laar IM, Oldenburg RA, Pals G, Roos-Hesselink JW, de Graaf BM, Verhagen JM, et al. Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis. Nat Genet. 2011; 43(2):126–5.
4. Lindsay ME, Schepers D, Bolar NA, Doyle JJ, Gallo E, Fert-Bober J, et al. Loss-of-function mutations in TGFBR2 cause a syndromic presentation of thoracic aortic aneurysm. Nat Genet. 2012;44(8):922–7.
5. Boileau C, Guo DC, Hanna N, Regalo ES, Dettaint D, Gong L, et al. TGFBR2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome. Nat Genet. 2012;44(8):916–21.
6. Mioha D, Guo DC, Hilhorst-Hofstee Y, van Kooten F, Atmajaa D, Overwater E, et al. SMAD2 mutations are associated with arterial aneurysms and dissections. Hum Mutat. 2015;36(12):1145–9.
7. Bertoli-Avella AM, Gillis E, Morisaki H, Verhagen JMA, de Graaf BM, van de Beek G, et al. Mutations in a TGF-beta ligand, TGF3, cause syndromic aortic aneurysms and dissections. J Am Coll Cardiol. 2015;65(13):1324–36.
8. Schepers D, Tortora G, Morisaki H, MacCarrick G, Lindsay M, Liang D, et al. A mutation update on the LDS-associated genes TGFBR2/3 and SMAD2/3. Hum Mutat. 2018;39(5):621–34.
9. Yang H, Luo M, Fu Y, Cao Y, Yin K, Li W, et al. Genetic testing of 248 Chinese aortopathy patients using a panel assay. Sci Rep. 2016;6:33002.
10. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17(5):405–24.
11. Luo M, Yang H, Yin K, Chen Q, Zhang J, Fan Y, Zhou Z, Chang Q, Genetic testing of 10 patients with features of Loeyts-Dietz syndrome. Clin Chim Acta. 2016;456:144–8.
12. Uike K, Matsushita Y, Sakai Y, Togao O, Nagao M, Ishizaki Y, et al. Systemic vascular phenotypes of Loeyts-Dietz syndrome in a child carrying a de novo R381P mutation in TGFBR2: a case report. BMC Res Notes. 2013;6:456.
13. Ben Amor M, Edoudt T, Gouya L, Goyau S, Chabot G, Tischkowitz M, Roschger P, Klauhofer K, Rauch F. Low bone mass and high material bone density in two patients with Loeyts-Dietz syndrome caused by transforming growth factor beta receptor 2 mutations. J Bone Miner Res. 2012;27(3):713–8.
14. Sakai H, Wissl R, Ikegawa S, It E, Numabe H, Watanabe Y, et al. Comprehensive genetic analysis of relevant four genes in 49 patients with Marfan syndrome or Marfan-related phenotypes. Am J Med Genet A. 2006; 140(16):1719–25.
15. Ki CS, Jin DK, Chang SH, Kim JE, Kim JW, Park BK, et al. Identification of a novel TGFBR2 gene mutation in a Korean patient with Loeyts-Dietz aortic aneurysm syndrome; no mutation in TGFBR2 gene in 30 patients with classic Marfan’s syndrome. Clin Genet. 2005;68(6):561–3.
16. Van Laer L, Dietz H, Loeyts B. Loeyts-Dietz syndrome. Adv Exp Med Biol. 2014; 802:95–105.
17. Goudie DR, D’Alessandro M, Merriman B, Lee H, Szeveryeni I, Avery S, et al. Multiple self-healing squamous epithelioma is caused by a disease-specific spectrum of mutations in TGFBR1. Nat Genet. 2011;43(4):365–9.
18. Shenueur C, Collod-Beroud G, Fauve L, Gouya L, Sultan G, Le Parc JM, et al. Identification of 23 TGFBR2 and 6 TGFBR1 gene mutations and genotype-phenotype investigations in 457 patients with Marfan syndrome type I and II, Loeyts-Dietz syndrome and related disorders. Hum Mutat. 2008;29(11):E284–95.
19. Canneaerts E, Kempers M, Maugeri C, Gardetchik T, Richer J, et al. Novel pathogenic SMAD2 variants in five families with arterial aneurysm and dissection: further delineation of the phenotype. J Med Genet. 2019; 56(4):220–7.
20. Attias D, Shenueur C, Roy C, Collod-Beroud G, Dettaint D, Fauve L, et al. Comparison of clinical presentations and outcomes between patients with TGFBR2 and FBN1 mutations in Marfan syndrome and related disorders. Circulation. 2009;120(25):2541–9.
21. Schoenhoff FS, Mueller C, Czemy M, Matyas G, Klaushofer K, Rauch F. Low bone mass and high material bone density in patients with Marfan syndrome type I and II, Loeyts-Dietz syndrome and related disorders. Eur J Cardiothorac Surg. 2014; 46(3):444–9 discussion 49.
22. Brownstein AJ, Kostiuk V, Ziganh B, Zafar MA, Kuhnani H, Body SC, Bale AE, Befenrides JA. Genes associated with thoracic aortic aneurysm and dissection 2018 update and clinical implications. Acta (Santoford). 2018(11):11–20.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions